# Alloplex Biotherapeutics

**Canonical:** https://apis.io/providers/alloplex-biotherapeutics/  
**Website:** https://alloplexbio.com/  
**APIs profiled:** 7

Alloplex Biotherapeutics, Inc. is a privately held clinical-stage cellular immunotherapy company founded in 2016 and headquartered in Woburn, Massachusetts, with a wholly owned subsidiary, Alloplex Australia Pty Ltd, in Adelaide, South Australia. It develops non-engineered, autologous multi-cellular therapies intended to retrain a patient's own immune system against solid tumors and autoimmune disease. Its ENLIST platform uses an irradiated, engineered melanoma cell line expressing multiple immunomodulatory factors to activate, differentiate and expand a patient's peripheral blood mononuclear cells; the resulting product, SUPLEXA, is manufactured by a defined, GMP-compatible process that uses no genetic engineering and no feeder cells and yields a full course of treatment from a small blood draw in roughly one month. The first-in-human Phase 1 SUPLEXA-101 trial, conducted in Australia in 35 patients with metastatic solid tumors who had exhausted standard options, met its endpoints, and the FDA granted SUPLEXA Fast Track designation for MSI-H colorectal cancer. Alloplex Biotherapeutics runs no developer program and publishes no product API, developer portal, SDK or API documentation; the only machine-readable surface reachable without credentials is the WordPress REST content API behind alloplexbio.com, catalogued here.

## Kin Score — 34.9 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 34.9).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 61.3 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 19.0 |
| Commercial Clarity | 34.2 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 33.1 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | partial |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (7)

- **Alloplex Biotherapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **Alloplex Biotherapeutics Media API** — Media library (225 attachments at harvest time), including PDF executive summaries and press assets.
- **Alloplex Biotherapeutics Oembed API** — oEmbed 1.0 provider endpoint for alloplexbio.com URLs.
- **Alloplex Biotherapeutics Pages API** — Corporate pages (19 published at harvest time) — About, Investors, Scientists, Information for Patients, Media and Press, Media Kit, FAQ, Releases and Updates, Terms of use, Pri...
- **Alloplex Biotherapeutics Posts API** — Press releases, scientific and clinical news, conference notes and opinion pieces (61 published at harvest time). Unlike many corporate WordPress deployments, content.rendered a...
- **Alloplex Biotherapeutics Search API** — Cross-content search across published posts and pages.
- **Alloplex Biotherapeutics Taxonomy API** — Categories and tags. Categories holds 11 terms (company-news, clinical-news, scientific-news, research-news, conferences, media-coverage, opinion, backgrounder, diary-marker, au...

## Security (2)

- **Alloplex Biotherapeutics Authentication** — 0 schemes
- **Alloplex Biotherapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, biotechnology, cell-therapy, immunotherapy, oncology, cancer, clinical-trials, life-sciences, drug-development, autoimmunity, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/alloplex-biotherapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.